WO2007115132A3 - Radiopharmaceutical in self-forming liposomal formulation capable of multipath administration including other ingredients - Google Patents

Radiopharmaceutical in self-forming liposomal formulation capable of multipath administration including other ingredients Download PDF

Info

Publication number
WO2007115132A3
WO2007115132A3 PCT/US2007/065553 US2007065553W WO2007115132A3 WO 2007115132 A3 WO2007115132 A3 WO 2007115132A3 US 2007065553 W US2007065553 W US 2007065553W WO 2007115132 A3 WO2007115132 A3 WO 2007115132A3
Authority
WO
WIPO (PCT)
Prior art keywords
radionuclide
self forming
liposome
self
tumor
Prior art date
Application number
PCT/US2007/065553
Other languages
French (fr)
Other versions
WO2007115132A2 (en
Inventor
F Timothy Guilford
Brooke Schumm Iii
Original Assignee
F Timothy Guilford
Brooke Schumm Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/011397 external-priority patent/WO2006105155A2/en
Priority claimed from PCT/US2006/060271 external-priority patent/WO2007053810A2/en
Application filed by F Timothy Guilford, Brooke Schumm Iii filed Critical F Timothy Guilford
Publication of WO2007115132A2 publication Critical patent/WO2007115132A2/en
Publication of WO2007115132A3 publication Critical patent/WO2007115132A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention is a composition containing a self forming liposome and a radionuclide for use in individuals undergoing radionuclide exposure for either diagnostic purposes or as a therapy using radioactively tagged tumor specific modalities. The radionuclide materials in general consist of a tumor targeting agent such as an antibody that targets tumor tissue to which a radioactive component has been attached. The self forming liposomes are constructed to be long circulating and of a size that to accumulate in tumor tissue. The self forming liposomes containing radionuclide agents can be used for tumor imaging to stage cancers, repeated imaging for monitoring and for therapeutic applications. The self forming liposome allows the encapsulation of the radionuclide material without adding additional energy to the composition to avoid damaging the radionuclide combination. The self forming liposome is capable of administration as an oral, topical, intraoral or transmucosal preparation. The invention also relates to the use of a second liposome encapsulation of a different composition utilized simultaneously or contemporaneously to supply reduced glutathione to the tissues not directly targeted by the self forming liposome in order to protect the non-targeted tissues from the effects of the radionuclide.
PCT/US2007/065553 2006-03-29 2007-03-29 Radiopharmaceutical in self-forming liposomal formulation capable of multipath administration including other ingredients WO2007115132A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
USPCT/US2006/011397 2006-03-29
PCT/US2006/011397 WO2006105155A2 (en) 2005-03-29 2006-03-29 Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms
US11/277,845 2006-03-29
US11/277,845 US20070077258A1 (en) 2005-03-29 2006-03-29 ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA INTRAVENOUS OR ENCAPSULATED IN LIPOSOME FOR THE AMELIORATION OF TNF-alpha EFFECTS AND FLU-LIKE VIRAL SYMPTOMS AND TREATMENT AND PREVENTION OF VIRUS
US86301506P 2006-10-26 2006-10-26
PCT/US2006/060271 WO2007053810A2 (en) 2005-11-06 2006-10-26 Liposomally encapsulated reduced glutathione, including with other pharmacologic preparation, capable of administration as an oral, topical, intraoral or transmucosal, preparation, for reversal and prevention of oxidation of cholesterol and of low density lipoprotein
USPCT/US2006/060271 2006-10-26
US60/863,015 2006-10-26

Publications (2)

Publication Number Publication Date
WO2007115132A2 WO2007115132A2 (en) 2007-10-11
WO2007115132A3 true WO2007115132A3 (en) 2008-10-30

Family

ID=38564227

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/065553 WO2007115132A2 (en) 2006-03-29 2007-03-29 Radiopharmaceutical in self-forming liposomal formulation capable of multipath administration including other ingredients
PCT/US2007/065552 WO2007115131A2 (en) 2004-11-07 2007-03-29 Liposomal reduced glutathione and 1-arginine, including other ingredient(s)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/065552 WO2007115131A2 (en) 2004-11-07 2007-03-29 Liposomal reduced glutathione and 1-arginine, including other ingredient(s)

Country Status (1)

Country Link
WO (2) WO2007115132A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166846A1 (en) * 2008-12-31 2010-07-01 Guilford F Timothy Management of myoclonus with oral liposomal reduced glutathione
US20150216925A1 (en) * 2012-02-15 2015-08-06 Kyowa Hakko Bio Co., Ltd. Agent for preventing or ameliorating vascular endothelial malfunction
WO2013122188A1 (en) * 2012-02-15 2013-08-22 協和発酵バイオ株式会社 Agent for preventing or ameliorating vascular endothelial malfunction
US20140023696A1 (en) * 2012-07-20 2014-01-23 Frederick Timothy Guilford Treatment for idiopathic pulmonary fibrosis
US20140234397A1 (en) * 2013-02-15 2014-08-21 Lou Ann Brown Treatment of klebsiella pneumoniae with liposomally formulated glutathione
EP2956153A4 (en) * 2013-02-15 2017-03-22 Your Energy Systems, LLC Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione
WO2016053899A1 (en) * 2014-09-29 2016-04-07 Your Energy Systems, LLC Method of treatment using liposomally formulated reduced glutathione to cooperate with il-10 to modulate inflammatory response triggered in hiv+ andtb immune-compromised diabetic patients

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143713A (en) * 1990-05-30 1992-09-01 Board Of Regents, The University Of Texas System 99m Tc labeled liposomes
US20020122768A1 (en) * 2000-07-06 2002-09-05 Shuang Liu Stable radiopharmaceutical compositions and methods for preparation thereof
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US20050222396A1 (en) * 2002-07-02 2005-10-06 Ande Bao Radiolabeled compounds and liposomes and their method of making and using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69323731T2 (en) * 1992-11-10 1999-07-22 Otsuka Pharma Co Ltd FOOD COMPOSITION
US6500165B1 (en) * 1998-10-29 2002-12-31 Steven R. Frank Active antisepsis device
PT1133312E (en) * 1999-06-21 2007-11-30 Lilly Co Eli Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
US6544994B2 (en) * 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143713A (en) * 1990-05-30 1992-09-01 Board Of Regents, The University Of Texas System 99m Tc labeled liposomes
US20020122768A1 (en) * 2000-07-06 2002-09-05 Shuang Liu Stable radiopharmaceutical compositions and methods for preparation thereof
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US20050222396A1 (en) * 2002-07-02 2005-10-06 Ande Bao Radiolabeled compounds and liposomes and their method of making and using same

Also Published As

Publication number Publication date
WO2007115131A2 (en) 2007-10-11
WO2007115132A2 (en) 2007-10-11
WO2007115131A3 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
Fan et al. Breaking the depth dependence by nanotechnology‐enhanced X‐ray‐excited deep cancer theranostics
WO2007115132A3 (en) Radiopharmaceutical in self-forming liposomal formulation capable of multipath administration including other ingredients
Chen et al. Hyperthermia-mediated local drug delivery by a bubble-generating liposomal system for tumor-specific chemotherapy
Koukourakis Sofia Koukouraki, Alexandra Giatromanolaki, Stelios Kakolyris, Vassilis Georgoulias, Antigoni Velidaki, Spyridon Archimandritis and Nikolaos N. Karkavitsas High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas: rationale for combination with radiotherapy
Soundararajan et al. [186Re] Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model
Chang et al. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model
KR20130019029A (en) Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy
Vairo et al. Preclinical safety of topically administered nanostructured lipid carriers (NLC) for wound healing application: biodistribution and toxicity studies
US20130090591A1 (en) Localization of agents at a target site with a composition and an energy source
NO20074362L (en) Pharmaceutical preparation containing magnetic vesicular particles, process for their preparation, and diagnostic therapeutic system
AR011133A1 (en) CONTROLLED RELEASE MICROGRANULES CONTAINING CISPLATINE, PROCEDURE FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITION AND USE IN THE MANUFACTURE OF A POLYCHIMOTHERAPY MEDICATION OR IN ASSOCIATION WITH RADIOTHERAPY.
CN115697413A (en) Radiopharmaceuticals and imaging agents targeting FAP and uses related thereto
Mangoni et al. A PPAR-gamma agonist attenuates pulmonary injury induced by irradiation in a murine model
Shih et al. Therapeutic and scintigraphic applications of polymeric micelles: combination of chemotherapy and radiotherapy in hepatocellular carcinoma
von der Maase et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium
Wagner et al. The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC)
Bolla et al. Ten year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC study
Meerovich et al. Low-intensity light-induced drug release from a dual delivery system comprising of a drug loaded liposome and a photosensitive conjugate
Chang et al. External beam radiotherapy synergizes 188Re-liposome against human esophageal cancer xenograft and modulates 188Re-liposome pharmacokinetics
JP7438756B2 (en) Targeted radiotherapeutic chelates for in situ immunomodulatory cancer vaccination
Miao et al. Therapeutic efficacy of a 177Lu-labeled DOTA conjugated α-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model
CA2798205A1 (en) Imageable activatable agent for radiation therapy and method and system for radiation therapy
Meng et al. Nuclear factor-kappa B inhibition can enhance therapeutic efficacy of 131I on the in vivo management of differentiated thyroid cancer
Oratz et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma
Sadeghi et al. 99mTc-Glucarate for assessment of paclitaxel therapy in human ovarian cancer in mice

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07759744

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07759744

Country of ref document: EP

Kind code of ref document: A2